Most biotechs don't have any revenue when they go public. They are traded on scientific progress through clinical trials. The idea being that if they do get through a phase 3, they are immediately valuable since they have a monopoly on a valuable therapeutic. Most likely, they get acquired by large pharma before that point - see Kite & Gilead.